Anlon Healthcare Limited (AHCL)

Loading page…

Anlon Healthcare Limited (AHCL) · mywealthgrid

About

Anlon Healthcare Limited operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹2

Market cap

₹175 Cr

P/E

6.1×

P/B

0.8×

Dividend yield

ROE

12.4%

ROCE

17.4%

Debt / equity

0.19

OPM

27.6%

EPS (TTM)

₹5.4

Book value

₹43.3

52-week high

—

52-week low

—

264 historical price candles were omitted because the exchange source has not been verified.

₹32.9-9.7%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 27.6%
+Comfortable interest coverage of 12.4×

Cons

No red flags triggered.

Research score

Structured signal from quality, growth, valuation and momentum.

82/100

Business quality: 64
Valuation: 100

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2026
Revenue	172
COGS	105
Gross profit	67
	19
	48
OPM %	27.6%
Depreciation	2
Interest	4
	0
Profit before tax	43
Tax	13
Tax %	31.6%
PAT	29
PAT margin %	16.9%
EPS (₹)	6.1
EPS adjusted (₹)	0.5

₹ Cr	Mar 2026
Equity capital	53
Reserves	177
Minority interest	25
	44
	76
Total equity & liabilities	374
	58
CWIP	—
Investments	1
	315
Total assets	374

₹ Cr	Mar 2026
	-79
	-36
	119
Net cash flow	3
Free cash flow	-79
CFO / Operating profit %	-167.2%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: 11%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2026
Margins
Gross margin %	38.9%
EBITDA margin %	27.6%
EBIT margin %	26.7%
PAT margin %	16.9%
Working capital
Receivable days	220
Inventory days	393
Payable days	147
NWC days	467
Leverage
Current ratio	2.87
Debt to EBITDA	0.92
Debt to equity	0.19
Interest coverage	12.4
Asset turnover	0.46
Return ratios
Return on assets %	7.8%
Return on capital employed %	17.4%
Return on equity %	12.6%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	52.68%	52.68%	52.68%	52.68%	52.68%
	14.42%	0%	0.23%	0.32%	1.67%
	4.35%	2.83%	4.49%	4.6%	1.22%
Government	0%	0%	0%	0%	0%
	28.55%	44.49%	42.6%	42.4%	44.43%
No. of shareholders	—	12,464	11,412	12,484	34,671

Promoter holding up 0 percentage points since Jun 2025.

128 deals · 3 Sept 2025 – 30 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
30 Sept 2026	NEO APEX SHARE BROKING SERVICES LLP	Bulk	NSE	Buy	52,08,869	₹34.66	₹18.05 Cr
30 Sept 2026	NEO APEX SHARE BROKING SERVICES LLP	Bulk	NSE	Sell	27,01,691	₹34.62	₹9.35 Cr
25 Sept 2026	HRTI PRIVATE LIMITED	Bulk	NSE	Sell	72,44,905	₹30.20	₹21.88 Cr
25 Sept 2026	HRTI PRIVATE LIMITED	Bulk	NSE	Buy	72,25,426	₹30.10	₹21.75 Cr
25 Sept 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	32,98,433	₹30.15	₹9.94 Cr
25 Sept 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	32,90,123	₹30.13	₹9.91 Cr
25 Sept 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	32,18,674	₹30.13	₹9.70 Cr
25 Sept 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	32,12,893	₹30.16	₹9.69 Cr
25 Sept 2026	QE SECURITIES LLP	Bulk	NSE	Sell	28,25,885	₹29.87	₹8.44 Cr
25 Sept 2026	PLUTUS WEALTH MANAGEMENT LLP	Bulk	NSE	Sell	27,29,252	₹29.91	₹8.16 Cr

1–10 of 128

1 / 13

Mr. PUNITKUMAR RAMESHBHAI RASADIAExecutive Director-Chairperson-MD
Mr. MEET ATULKUMAR VACHHANIExecutive Director
Mrs. MAMATA PUNITKUMAR RASADIANon-Executive - Non Independent Director
Mr. KRISHNA MURTY KANNEPALLINon-Executive - Independent Director
Mr. ANANDBHAI NATWERLAL KATKORIANon-Executive - Independent Director
Mr. KISHAN VINODKUMAR RAJANon-Executive - Independent Director
Mr. Naimish Dilipbhai BhattChief Financial Officer
Amita Chhaganbhai PragadaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Anlon Healthcare Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results30 Jul 2026

1

Face value ₹10 → ₹224 Apr 2026 · ex-date

1

Bonus 1:124 Apr 2026 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

139 announcementsExport CSV

29 Sept 2026, 6:44 pmBoard Meeting

Board Meeting Intimation for Company''s Business Expansion Plans In India And/Or Overseas, And The Raising Of Funds/ Financing Thereof, In One Or More Tranches,

Exchange filing PDF

28 Sept 2026, 8:47 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

21 Sept 2026, 3:10 pmCompany Update

Announcement For Incorporation Of Foreign Subsidiary Of The Company

General PDF

21 Sept 2026, 3:02 pmCompany Update

Announcement As Per Regulation 30 Of SEBI LODR.

General PDF

17 Sept 2026, 12:07 pmCompany Update

Clarification On Price Movement

General PDF

16 Sept 2026, 5:41 pmCompany Update

Clarification sought from Anlon Healthcare Ltd

Clarification

15 Sept 2026, 12:21 pmCompany Update

Announcement under Regulation 30 (LODR)-Credit Rating

Credit Rating PDF

7 Sept 2026, 1:53 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

Date	Category	Subject	Filing
29 Sept 2026, 6:44 pm	Board Meeting	Board Meeting Intimation for Company''s Business Expansion Plans In India And/Or Overseas, And The Raising Of Funds/ Financing Thereof, In One Or More Tranches,	PDF
28 Sept 2026, 8:47 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window

Loading announcements…

Anlon Healthcare Limited

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Return on equity

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

1

1

1

Announcements

Not in the F&O segment

1

1

1

No fund holdings on record

Announcements

Offer and rights documents

Credit ratings

Investor Presentation and earnings call

Return on equity

Anlon Healthcare Limited

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Stock splits1

Bonus issues1

Announcements

Not in the F&O segment

Ratio timeline

Board meetings1

Stock splits1

Bonus issues1

No fund holdings on record

Quarterly record

Bulk & block deals

Board and management

Announcements

Offer and rights documents

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Return on equity

1

1

1

1

1

1